Treatment of Polymyositis in Adults with Chronic Interstitial Lung Disease

When polymyositis occurs alongside chronic interstitial lung disease, the clinical picture demands a tailored treatment strategy. This protocol is designed for adults aged 18 years or older presenting with this specific combination.

Clinical Scenario

Adults aged 18 years or older with polymyositis and concurrent chronic interstitial lung disease.

Treatment Approach

For patients with treatment-resistant disease in this setting, the protocol calls for specific immunosuppressive agents. The complete selection criteria, decision pathway, and full regimen are available in the structured protocol.

Full regimen details are accessible via the protocol link below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/rheumatology/keac115

Rituximab or cyclophosphamide is to be considered in treatment-resistant patients.

View source ↗